Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Formative Research

Date Submitted: Jan 10, 2021
Date Accepted: Aug 17, 2022

The final, peer-reviewed published version of this preprint can be found here:

Patients’ and Health Care Providers’ Perceptions on mHealth Use After High-Altitude Climate Therapy for Severe Asthma: Mixed Methods Study

Khusial R, van Koppen S, Honkoop P, Rijssenbeek-Nouwens L, Keij S, Drijver-Messelink M, Sont J

Patients’ and Health Care Providers’ Perceptions on mHealth Use After High-Altitude Climate Therapy for Severe Asthma: Mixed Methods Study

JMIR Form Res 2022;6(11):e26925

DOI: 10.2196/26925

PMID: 36413384

PMCID: 9727687

Davos@home, patient and healthcare providers’ perceptions on mHealth use after high altitude climate therapy in severe asthma: a mixed methods study.

  • Rishi Khusial; 
  • Sofie van Koppen; 
  • Persijn Honkoop; 
  • Lous Rijssenbeek-Nouwens; 
  • Sascha Keij; 
  • Marieke Drijver-Messelink; 
  • Jacob Sont

ABSTRACT

Background:

High Altitude Climate Therapy (HACT) includes environmental trigger avoidance in the alpine climate with multidisciplinary clinical treatment. Patients with severe and/or difficult-to-control asthma, who are unable to reach asthma control at sea-level, can follow a 12-week lung rehabilitation program at 1600 meters above sea level. Mobile health (mHealth) tools can be used to enhance self-management in these patients when they return home. In order for an mHealth application to be effective, it needs to meet the expectations of the end-users.

Objective:

In this Davos@home study we explored the attitudes towards mHealth of severe difficult-to-control asthma patients who underwent HACT and asthma healthcare providers (HCP).

Methods:

Interviews with referrers to HACT, and focus groups with asthma patients who participated in or finished HACT were conducted. Data were analysed thematically. Based on these results a questionnaire was developed. In the second stage of the study this questionnaire, combined with the Asthma Control Questionnaire and the Individual Innovativeness Questionnaire, was distributed to patients who finished HACT.

Results:

In total 11 interviews and 3 focus groups (n=18, age 47.6, ACQ 2.6) were conducted. Three themes were identified: potential goals, useful measurements, and perceived barriers and facilitators. The questionnaire included items based on the these results. The most agreed upon goal among the 64 patients who filled out the questionnaire was increasing their asthma control (84% of the patients).

Conclusions:

Different patients reported they would benefit the most from different measures. Therefore it is important to take individual (treatment) goals into consideration. When developing a mHealth intervention it is important to have personalisation options available in order to ensure not to overwhelm the users. Clinical Trial: The study was approved by the Medical Ethics Committee of Leiden University Medical Center P19.039).


 Citation

Please cite as:

Khusial R, van Koppen S, Honkoop P, Rijssenbeek-Nouwens L, Keij S, Drijver-Messelink M, Sont J

Patients’ and Health Care Providers’ Perceptions on mHealth Use After High-Altitude Climate Therapy for Severe Asthma: Mixed Methods Study

JMIR Form Res 2022;6(11):e26925

DOI: 10.2196/26925

PMID: 36413384

PMCID: 9727687

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.